Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha

US12240840B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Steven H. Spergel · Warrington, US
• William J. Pitts · Newtown, US
• Michael E. Mertzman · New Hope, US
• Ryan M. Moslin · Princeton, US
• Trevor C. Sherwood · Plainsboro, US
• John L. Gilmore · Yardley, US
• Alaric J. Dyckman · Lawrenceville, US

Key dates

• Filing date: Oct 28, 2019
• Grant date: Mar 4, 2025
• Expiry date: Apr 17, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.